Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3079514 in Healthy Subjects
NCT02242903Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LY3079514 with Placebo (2 arms). Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2014; status: completed.
02
Drugs
LY3079514
Beyond the preview
Go deeper on NCT02242903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242903.